Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib

Although sorafenib is expected to have a chemopreventive effect on hepatocellular carcinoma (HCC) recurrence, there are limitations to its use because of adverse effects, including effects on liver function. We have reported that the iron chelator, deferoxamine can prevent liver fibrosis and preneop...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Biochem Nutr
Main Authors: Yamamoto, Naoki, Yamasaki, Takahiro, Takami, Taro, Uchida, Koichi, Fujisawa, Koichi, Matsumoto, Toshihiko, Saeki, Issei, Terai, Shuji, Sakaida, Isao
Formato: Artigo
Idioma:Inglês
Publicado: the Society for Free Radical Research Japan 2016
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4865599/
https://ncbi.nlm.nih.gov/pubmed/27257345
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3164/jcbn.15-127
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares